Vascular Closure System Enables Same-Day Discharge – Surgical Techniques


Image: The Vascade MVP System places a patch of collagen into the ablation access sites (Photo courtesy of Haemonetics)

An innovative venous vascular closure device enables same-day discharge after cardiac ablation for atrial fibrillation (AF).

The Vascade MVP from Haemonetics (Braintree, MA, USA) is an integrated vascular closure system that combines a small, collapsible, low-profile nitinol mesh biconvex disc and thrombogenic collagen hemostatic patches to accelerate clotting at the site of access after cardiac electrophysiology procedures. The mesh disc is first brought close to the inner wall of the vessel wall to temporarily quench the bleeding; a patch of collagen is then released into the tissue tract, expanding approximately 13 times, and the mesh disc is then removed.

The expanded collagen ensures that the residual tissue tract is sufficiently filled after completion of the ablation procedure and is quickly resorbed, allowing future access procedures. The Vascade MVP System has been shown to reduce walking time, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients undergoing catheter-based procedures using procedural sheaths inside diameter 6-12F, with one or more -access sites in one or both limbs.

“COVID has accelerated the need to improve safety and efficiency to significantly optimize the patient experience,” said Chris Simon, President and CEO of Haemonetics. “Vascade’s achievement of the first and only same-day discharge indication for AF ablation patients demonstrates our leadership in the industry and our continued commitment to improving standards of care.”

Vascular access complications are common, and a host of strategies have therefore been developed to decrease access site bleeding and complications. Closure devices have emerged as an alternative to traditional mechanical compression, as they can reduce total time to hemostasis, reduce patient discomfort associated with prolonged bed rest, improve early mobilization and patient satisfaction, and reduce health expenditure.

Related links:

Hemonetics

Previous Danimer Scientific, Inc. (NYSE: DNMR) Long-term investor
Next Italian captain sentenced to prison for taking migrants to Libya